Pfizer (PFE)

Koyfin analysts expect revenue to grow nearly 28% from the last quarter and forecast losses to narrow significantly.

The global landscape of HIV prevention and treatment has reached a historic turning point following the clinical triumph and subsequent commercial launch of Gilead Sciences’ (Nasdaq: GILD) lenacapavir, now marketed as Yeztugo. As of February 25, 2026, the biopharmaceutical giant has successfully transitioned from a provider of daily oral regimens

Eli Lilly has seen revenue and earnings soar in recent years.

Pfizer stock rises after FDA fully approves Braftovi combo for metastatic colorectal cancer with BRAF V600E mutation.

Novo Nordisk now trades at just 10.6x earnings after a 58% crash, far below Eli Lilly, Vertex, and Pfizer — signaling a valuation reset.

Due to Pfizer’s underperformance relative to the healthcare sector over the past year, Wall Street analysts remain cautious about the stock’s prospects

According to data from Fiscal AI, Novavax is expected to report a quarterly loss per share of $0.55, higher than the loss of $0.52 reported in the corresponding quarter of 2024.

Pfizer says it is standing behind its dividend, which makes the stock's 6.4% yield quite attractive.

Data from Stocktwits indicated retail sentiment on SPY and QQQ remained ‘bearish’ on Stocktwits.

The undisputed reign of Novo Nordisk in the weight-loss drug sector faced its most severe challenge to date on February 23, 2026, as the company’s US-traded shares (NYSE: NVO) plummeted 15.1% in a single session. The massive sell-off, which erased approximately $100 billion in market capitalization, was triggered

In a pivotal moment for the consumer health landscape, Kenvue (NYSE: KVUE) has reported a robust set of fourth-quarter results for 2025, signaling a successful turnaround and strategic resilience just months after the announcement of its blockbuster merger. On February 17, 2026, the company revealed that its Q4 net sales

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.

Celcuity develops targeted cancer therapies and diagnostic platforms, with a focus on advancing precision medicine in oncology.

There are several solid prospects to choose from right now, but there's a reason I can't get these particular names out of my head.

Is Pfizer's 6% yield a rare opportunity hiding in plain sight, or are investors overlooking a major risk that could reshape its future?

Pfizer is playing catch-up in the GLP-1 drug space, but the drugmaker has a long history of success.

New products are already generating growth.

Eli Lilly is leading the pack in the GLP-1 weight-loss drug market, but this good news won't last forever.

NEW YORK — Pfizer Inc. (NYSE: PFE) has announced breakthrough results from its Phase 3 BREAKWATER clinical trial, demonstrating that its BRAFTOVI (encorafenib) regimen significantly improves both progression-free survival (PFS) and overall survival (OS) in patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC). The data, bolstered by a fresh topline report

If you are looking for high-yield stocks, these two turnaround stories offer yield and green shoots, suggesting better times are ahead.

Data from Stocktwits indicated retail sentiment towards SPY and QQQ cooled to neutral.

Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit growth as expanding further becomes an increasingly challenging task.

Optimism also grew around FDA momentum for its palmoplantar pustulosis drug ahead of MoonLake’s Feb. 23 investor day.

A robust pipeline is essential for a buy-and-hold pharmaceutical stock.